Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
2(50.0%)
4Total
N/A(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06892093Not ApplicableRecruiting

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

Role: collaborator

NCT05549778Phase 1Completed

Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC

Role: lead

NCT04911556Not ApplicableUnknown

the Effect of Probiotics on Aging Population

Role: collaborator

NCT04839055Phase 1Unknown

The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC

Role: lead

All 4 trials loaded